The short answer
The MHRA reported in January 2026 that it seized illegal medicines worth almost £45 million during 2025: nearly 20 million doses in total, including more than 5,000 illegally traded GLP-1 products.
Key facts
- Reported
- 26 January 2026, gov.uk
- Total value
- Almost £45 million
- Total doses
- Almost 20 million
- GLP-1 products
- More than 5,000 illegally traded
- Quoted
- Andy Morling, Deputy Director, Enforcement
- Related action
- Northampton facility, October 2025
What the figures cover
All illegally traded medicines, not weight-loss products alone. Nearly 20 million doses across the year, valued at almost £45 million, which the agency described as more illegally traded medicine removed from circulation than in any previous year.
Where GLP-1 products sit within it
More than 5,000 illegally traded GLP-1 products. Against 20 million doses overall that is a small fraction by count and a highly disproportionate one by attention, cost and clinical risk. These are injectables with no verified contents, sold into a market with extraordinary demand.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why enforcement scaled up when it did
Demand created margin. When a licensed medicine is expensive, supply-constrained and desired by very large numbers of people, the incentive to manufacture and sell unauthorised versions rises accordingly. The Northampton facility dismantled in October 2025 is what that incentive produces at industrial scale.
What the agency said
Andy Morling, Deputy Director for Enforcement, was quoted saying that working with law enforcement partners the agency had removed more illegally traded medicines from circulation than ever before, and urging people to think very carefully before buying powerful medicines online.
How the framework decides what is illegal
Not the molecule. Supplying a medicinal product without authorisation is the offence, and what makes something a medicinal product includes how it is presented and what it is offered for. A compound supplied as unformulated laboratory material with no therapeutic claim sits outside that; the same compound in a labelled pen sold for injection does not.
What this means for how this site is written
Every article here reports what published research measured and in which model or population. None claims that any compound treats, prevents or improves anything in any person, and none provides dosing or administration guidance. That is a deliberate response to the framework these enforcement figures describe.
Frequently asked questions
How much did the MHRA seize in 2025?
Almost £45 million of illegal medicines: nearly 20 million doses, including more than 5,000 illegally traded GLP-1 products.
Does the law target specific compounds?
No. The offence is supplying a medicinal product without authorisation, which depends on presentation and claimed purpose rather than the molecule.
Why did GLP-1 enforcement increase?
High demand for an expensive, supply-constrained licensed medicine creates the margin that makes unauthorised manufacture profitable.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- The EMA Opinion on Oral Semaglutide for Weight ManagementOn 21 May 2026 the CHMP recommended adding oral tablets to Wegovy's authorisation in four strengths. What a positive opinion is, and what it is not.
- MARITIME: Where the Monthly Compound Is Being TestedMaridebart cafraglutide's Phase 3 programme spans obesity, sleep apnoea and heart failure - including a 5,056-participant cardiology trial.
- Reading a Programme From Its Trial RegistrationsOne trial was withdrawn with zero enrolment; three others are completed, active or recruiting. Withdrawn and terminated mean different things.
- What the Systematic Reviews Say About Children and AdolescentsTwo 2025 systematic reviews assessed GLP-1 agonists in children and adolescents. What review-level evidence establishes, and what is still missing.
- What the Human Studies Have FoundA BMJ Scandinavian cohort, a JAMA Network Open analysis of 13 cancers, and a 2025 meta-analysis of randomised trials. What each design can support.